Ennature Bio Pharma Limited (ENNATURE)
📈 Share price & events
📢 Recent Corporate Announcements
Ennature Bio Pharma Limited listed on the NSE and BSE on November 4, 2026, following its demerger from India Glycols Limited. In FY26, the company's biopharma division reported net revenue of ₹246 crore, EBITDA of ₹29 crore, and a gross margin of 40.1%. Plant-based APIs formed 67% of sales, while biopolymers and nutraceuticals contributed 16% and 17%, respectively. The company operates two manufacturing facilities in Dehradun (1,600 MT) and Kashipur (24,000 MT).
- Listed on NSE and BSE on November 4, 2026, following demerger from India Glycols Limited
- Reported FY26 net revenue of ₹246 crore, EBITDA of ₹29 crore, and gross margin of 40.1%
- API business generates 67% of revenue with 54% exports across 150+ customers
- Biopolymers and nutraceuticals contribute 16% and 17% of sales, with 69% and 83% export shares respectively
- Combined manufacturing capacity of 25,600 MT across Dehradun (1,600 MT) and Kashipur (24,000 MT)
Company profile
Financial Performance
Financial analysis data not yet available for this company.
Operational Drivers
Operational analysis data not yet available for this company.
Strategic Growth
Strategic growth analysis not yet available for this company.
External Factors
External factors analysis not yet available for this company.
Regulatory & Governance
Regulatory analysis not yet available for this company.
Risk Analysis
Risk analysis not yet available for this company.
